Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with breast and gynecological (initially ovarian) malignancies

Next Previous
Trial Profile

Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with breast and gynecological (initially ovarian) malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 26 Jun 2018 According to an Arcus Biosciences media release, status changed from planning to recruiting.
  • 26 Jun 2018 According to an Arcus Biosciences media release, Arcus Biosciences and Infinity Pharmaceuticals will also evaluate IPI-549 in combination with AB928 + AB122 as well as IPI-549 in combination with AB928 + chemotherapy in patients with triple negative breast cancer (TNBC) or ovarian cancer in four separate cohorts as part of this trial. Each of these four cohorts will enrol approximately 15 patients.
  • 11 Jun 2018 According to the Arcus Biosciences media release, the company has been completing the regulatory process to evaluate the combination of AB928 and AB122 in patients in Australia and expects to dose its first patient with this combination shortly.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top